Revolo Biotherapeutics Limited (“Revolo”) today announced that it will present two posters on its lead candidate, ‘1104, at the 2025 American Academy of Allergy Asthma and Immunology (AAAAI ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback